Evidence map›Paper›PMID 36068000›Full record

ArticleInvestigative and clinical urology2022

Changes in prostate-specific antigen kinetics during androgen-deprivation therapy as a predictor of response to abiraterone in chemonaïve patients with metastatic castration-resistant prostate cancer.

Chung-Lin Lee, Ying-Hsu Chang, Chung-Yi Liu, Ming-Li Hsieh, Liang-Kang Huang, Yuan-Cheng Chu, Hung-Cheng Kan, Po-Hung Lin, Kai-Jie Yu, Cheng-Keng Chuang and 3 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Investigative and clinical urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Chung-Lin LeeDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0003-1180-1973
Ying-Hsu ChangDepartment of Medicine, Chang Gung University, Taoyuan, Taiwan.ORCID 0000-0002-7265-6231
Chung-Yi LiuDepartment of Urology, New Taipei Municipal TuCheng Hospital, Chang Gung Memorial Hospital and Chang Gung University, New Taipei City, Taiwan.ORCID 0000-0002-6579-4775
Ming-Li HsiehDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0001-7815-4307
Liang-Kang HuangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0002-7634-6740
Yuan-Cheng ChuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0002-1210-0522
Hung-Cheng KanDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0003-1503-9971
Po-Hung LinDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0001-8245-4302
Kai-Jie YuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0003-3656-8856
Cheng-Keng ChuangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0001-6154-1220
Chun-Te WuDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0002-6910-9253
See-Tong PangDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0002-2064-0828
I-Hung ShaoDivision of Urology, Department of Surgery, Chang Gung Memorial Hospital, Linkou Branch, Linkou, Taiwan.ORCID 0000-0002-4832-0113
Chang Gung Memorial Hospital · TWChang Gung University · TW

Funding

Chang Gung Memorial Hospital CMRPG3K1931
6 · The paper itself

Abstract

purposeMetastatic castration-resistant prostate cancer (mCRPC) has a poor prognosis. Abiraterone acetate (AA), enzalutamide, and chemotherapy are first-line treatments for patients with mCRPC. This study examined prognostic factors for AA response in the form of prostate-specific antigen (PSA) kinetics throughout androgen-deprivation therapy (ADT) in chemonaïve patients with mCRPC. MATERIALS AND

methodsWe retrospectively included data from 34 chemonaïve patients with mCRPC who had received AA at some point between January 2017 and December 2018. We separated patients into two study arms according to the decrease in PSA percentages after use of AA for 3 months. We correlated PSA kinetics parameters with response and compared the two study groups with respect to PSA kinetics.

resultsThe patients' median age was 77 years. In the total group of patients, 64% had a response to AA, whereas 35% did not. The ratio of the PSA level at nadir to the level during ADT was significantly higher in the AA-sensitive group (19.78 vs. 1.03, p=0.019).

conclusionsPatients who experienced a dramatic change in PSA level during ADT were more likely to be resistant to AA after progression to mCRPC. Chemotherapy rather than AA might be more suitable as a first-line treatment for these patients.

Indexed as

Prostate-Specific AntigenProstatic Neoplasms, Castration-ResistantAbiraterone AcetateAgedAndrogen AntagonistsAndrogensAndrostenesHumansKineticsMaleRetrospective StudiesTreatment OutcomeabirateroneAbiraterone AcetateAndrogen AntagonistsAndrogensAndrostenesProstate-Specific AntigenNonsteroidal anti-androgensPrognosisProstate-specific antigenProstatic neoplasms

Identifiers

PMID36068000
PMCPMC9448667
OpenAlexW4288062087

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.